Subcorneal Pustular Dermatosis as a Complication of Upadacitinib Therapy in a Patient with Atopic Dermatitis: A Case Report
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0900Keywords:
atopic dermatitis, drug-related side effects, eczema, JAK inhibitors, janus kinase inhibitor, adverse drug reactionDownloads
References
Molla A, Alahmadi M, Alghamdi S, Humedi A, Alfaraj M, Bakhamees B, et al. The efficacy and safety of upadacitinib in atopic dermatitis: A systematic review and meta-analysis. Medicine (Baltimore) 2025; 104: e45239. DOI: https://doi.org/10.1097/MD.0000000000045239
Ibba L, Falcidia C, Di Giulio S, Bianco M, Valenti M, Facheris P, et al. Real-World effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermEffectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. J Clin Med 2025; 14: 2953. DOI: https://doi.org/10.3390/jcm14092953
Zhang C, Fu Z, Liu J, Li S, Chen X, Zhang Y, et al. Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis. Front Pharmacol 2025; 16: 1598972. DOI: https://doi.org/10.3389/fphar.2025.1598972
Paganini C, Mortato E, Tofani L, Belcastro A, Talamonti M, Di Raimondo C, et al. Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies. Dermatol Reports 2025; 17: 10193. DOI: https://doi.org/10.4081/dr.2025.10193
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–2168. DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Kremenevski I, Sander O, Sticherling M, Raithel M. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int 2022; 119: 88–95. DOI: https://doi.org/10.3238/arztebl.m2022.0067
Zhang Y, Jiang G. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Front Immunol 2024; 15: 1341632. DOI: https://doi.org/10.3389/fimmu.2024.1341632
Pastukhova E, Spurr A, Nakonechny Q, Lipson J. Upadacit inib-induced paradoxical face and scalp dermatitis: A case report of a novel sequela. SAGE Open Med Case Rep 2023; 11: 2050313X231164271. DOI: https://doi.org/10.1177/2050313X231164271
Bhargava S, Kumar U, Kroumpouzos G. Subcorneal pustular dermatosis: Comprehensive review and report of a case presenting during pregnancy. Int J Womens Dermatol 2020; 6: 131–136. DOI: https://doi.org/10.1016/j.ijwd.2020.02.003
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
